- Home
- DMAC vs IGI Comparison
DMAC vs IGI Comparison
Compare DMAC & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- IGI
- Stock Information
- Founded
- DMAC 2000
- IGI 2009
- Country
- DMAC United States
- IGI United States
- Employees
- DMAC N/A
- IGI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- IGI Investment Managers
- Sector
- DMAC Health Care
- IGI Finance
- Exchange
- DMAC Nasdaq
- IGI Nasdaq
- Market Cap
- DMAC 172.7M
- IGI 180.3M
- IPO Year
- DMAC N/A
- IGI N/A
- Fundamental
- Price
- DMAC $4.18
- IGI $16.64
- Analyst Decision
- DMAC Strong Buy
- IGI
- Analyst Count
- DMAC 3
- IGI 0
- Target Price
- DMAC $7.00
- IGI N/A
- AVG Volume (30 Days)
- DMAC 46.2K
- IGI 33.9K
- Earning Date
- DMAC 11-13-2024
- IGI 01-01-0001
- Dividend Yield
- DMAC N/A
- IGI 4.79%
- EPS Growth
- DMAC N/A
- IGI N/A
- EPS
- DMAC N/A
- IGI N/A
- Revenue
- DMAC N/A
- IGI N/A
- Revenue This Year
- DMAC N/A
- IGI N/A
- Revenue Next Year
- DMAC N/A
- IGI N/A
- P/E Ratio
- DMAC N/A
- IGI N/A
- Revenue Growth
- DMAC N/A
- IGI N/A
- 52 Week Low
- DMAC $2.14
- IGI $15.13
- 52 Week High
- DMAC $4.95
- IGI $17.79
- Technical
- Relative Strength Index (RSI)
- DMAC 48.23
- IGI 36.44
- Support Level
- DMAC $3.96
- IGI $16.50
- Resistance Level
- DMAC $4.21
- IGI $16.70
- Average True Range (ATR)
- DMAC 0.18
- IGI 0.13
- MACD
- DMAC -0.02
- IGI 0.02
- Stochastic Oscillator
- DMAC 50.00
- IGI 29.81
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About IGI Western Asset Investment Grade Defined Opportunity Trust Inc.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.